Category: Consumption Devices

Wildflower Enters Distribution Agreement

VANCOUVER, British Columbia, March 22, 2018: Wildflower Marijuana Inc. (CSE: SUN) (FWB: RSP) (“Wildflower” or the “Company”) entered into a Procurement and Transfer of Goods Agreement with one of California’s largest distributors through its licensed partner. As part of this agreement, Wildflower has entered into a Marketing Program Agreement to support sales. The structure of this arrangement is in order to comply with California regulations and replaces the previous agreement through which King products were being distributed. The agreement contemplates the future sale of Wildflower branded products as soon as available within the regulated market. With the acquisition of the multiple California licenses announced on March 19, 2018, Wildflower will have the ability to manufacture its products in Los Angeles and sell through one of the largest distributors in California. Wildflower CEO, William MacLean stated, “We are pleased to have navigated the complex California regulatory requirements and finalized our distributor arrangement as this now paves the way for future purchase orders for King and Wildflower products. This distribution, combined with the ability to manufacture, will allow Wildflower to gain further market penetration into the world’s largest regulated cannabis market.” About Wildflower Marijuana Inc. Wildflower is a cannabis company focused on developing and designing branded cannabis products. Wildflower sells its CBD+ products online and to retailers throughout the US and also produces and markets its THC products in regulated cannabis...

Read More

Namaste Announces Non-Binding Term Sheet With Australian-Based Medical Cannabis Company Pharmacann Company Pty Ltd.

Vancouver, British Columbia, Canada – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N)(FRANKFURT: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that it has signed a nonbinding Terms Sheet (the “Terms Sheet”) with PharmaCann Pty Ltd. (“PharmaCann”), whereby Namaste will participate in an investment to purchase a 10% equity position in PharmaCann. PharmaCann currently operates with existing licenses to import, export and wholesale medical cannabis issued by the Australian Government Department of Health. Namaste’s investment in PharmaCann will be used by PharmaCann to proceed with its application to further secure a cultivation license. The Australian market represents a major component of Namaste’s current revenue, which is derived in hardware sales, and remains a primary focus of Namaste’s strategic initiatives as it looks to target the Australian medical cannabis industry. Namaste believes PharmaCann’s import, export and wholesale licenses bring immediate value to the Company and believes that PharmaCann has the ability to obtain a cultivation license which will further enhance Namaste’s ability to penetrate global markets. In addition to Namaste’s strategic investment in PharmaCann, the Terms Sheet outlines additional business ventures between both parties as outlined below. Key Terms: • Namaste will provide a cash investment for 10% equity in PharmaCann. • Namaste will purchase 250kg annually of medical cannabis for export to Canada under the Company’s wholly owned subsidiary Cannmart Inc. (“Cannmart”) for the next three-year, subject to approval by...

Read More

Namaste Announces Medical Cannabis Supply Agreement with Leading Jamaican Producer Marigold

Vancouver, British Columbia, Canada – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N)(FRANKFURT: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that it has signed a Medical Cannabis Supply Agreement (the “Supply Agreement”) with Marigold Projects Jamaica Ltd. (“Marigold”) under its wholly owned subsidiary, Cannmart Inc. (“Cannmart”), whereby Marigold will supply Cannmart with high quality Jamaican produced medical cannabis, to be imported by Cannmart from Jamaica and offered in the Company’s online marketplace, subject to approval by Health Canada and the Cannabis Licencing Authority. This Supply Agreement further supports Namaste’s vision of creating a diverse platform for medical patients to access high quality cannabis, sourced from both domestic and international producers. Key Terms of the Supply Agreement: • Cannmart will submit purchase orders to Marigold for medical cannabis. • Cannmart will import medical cannabis from Marigold, subject to approval by Health Canada. • Cannmart will be compliant with Marigold’s branding and pricing strategy. • Cannmart will be responsible for shipping and importation costs of the product. • Marigold will provide Cannmart with lab test reports for each purchase in advance and in accordance with Cannmart’s requirements under Canadian regulations. • Packaging of products will bear the Marigold brand logo. The Supply Agreement with Marigold exemplifies a major component of Namaste’s strategy in providing Canadian patients with access to high-quality imported medical cannabis. Marigold’s strong management team and extensive experience in...

Read More

Wildflower Acquires Retail and Cultivation Licenses in LA

VANCOUVER, British Columbia, March 19, 2018: Wildflower Marijuana Inc. (CSE: SUN) (FWB: RSP) (“Wildflower” or the “Company”) signs agreement to acquire multiple California marijuana licenses in the City of Los Angeles including the ownership of a property with a Pre-ICO operating dispensary and cultivation facility. Wildflower will acquire the maximum number of licenses one party may hold which will permit the Company to conduct any cannabis activity from seed to sale in the city of Los Angeles. The licenses include medicinal and adult use storefront and delivery, medicinal and adult use cultivation specialty indoor, medicinal and adult use manufacturer level 1 and medical and adult use distributor licenses for both dispensaries currently have the unique advantage of being able to relocate anywhere in the City of Los Angeles, irrespective of concentration limits imposed in each district of the City. Only PreICO applicants are being given licenses at this time. The next wave of licenses will fall under a social equity program and only the final wave of licenses will be open to the public. Currently there is no indication of when the second and third wave of licensing will occur. Consideration for the purchase of the licenses, the property and the fixtures comprising the dispensary and the grow operation is US$10.2M and the issuance of 200,000 common shares. The agreement is subject to due diligence, negotiation of a definitive...

Read More

Namaste Announces LOI with Inolife R&D to Conduct a Research Study to Evaluate Needle-Free Injection Technologies for Medical Cannabis

SHARE THIS POST Vancouver, British Columbia, Canada – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N) (FRA: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that it has signed a non-binding LOI with Inolife R&D Inc. (“Inolife”), whereby Namaste and Inolife will negotiate the terms of a definitive agreement (the “Agreement”) to initiate a research study to evaluate applications for Inolife’s proprietary needle-free injectors in the medical cannabis industry. Under the terms of the LOI and proposed Agreement, Namaste will hold exclusive rights to research and distribute Inolife’s needle-free injection technologies for applications in the cannabis industry. Namaste will also participate in Inolife’s anticipated private placement by acquiring up to 10% of the shares issued under the offering. Inolife will also provide Namaste with the right to acquire up to an additional 10% of the shares issued under the offering at the same price. Additionally, Namaste will purchase up to 10% of the shares issued in connection with Inolife’s go-public transaction for approximately $250,000. Namaste believes that Inolife’s needle-free technologies could revolutionize dosage and administration of cannabis for medical purposes. The LOI and proposed Agreement represent a strategic initiative for Namaste’s continued effort to offer innovative products to the medical cannabis market. Namaste believes that Inolife’s technology provides the most accurate and efficient method for dosing with medical cannabis. Namaste expects to work within Health Canada’s current and future...

Read More

Namaste Announces February 2018 Sales of C$1.37M Representing a 146% Year-over-Year Increase and Provides Update on Namaste MD

SHARE THIS POST Vancouver, British Columbia, Canada – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N) (FRA: M5BQ) (OTCMKTS: NXTTF) is pleased to announce February 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,370,442, representing a 146% revenue increase in February 2018 compared with February 2017. February is a historically low month for sales and as such, the Company is pleased with these results. Management anticipates these year-on-year growth trends to continue as the Canadian market moves towards cannabis legalization and the Company executes its strategy to expand sales in emerging markets. The table below outlines gross sales of Namaste’s major sites and includes site traffic, conversion rates, total number of orders per site and average online basket price. Namaste Net Revenues – February 2018 (C$) Namaste 617,733 EDIT 168,353 Australian Vaporizers 322,088 Drop Shipping 94,563 Other Channels 167,705 Total Net Revenues $1,370,442 Below are revenues of the major sites operated by the Company.   Traffic Total Orders Conversion Revenues Avg. Order Price Namaste 150,547 2,940 1.95% 617,733 210 Australian Vaporizers 40,212 2,080 5.17% 322,088 155 EDIT 202,937 2,302 1.13% 168,353 73 Total 393,696 7,322 1.86% $1,108,174 $151 In addition to announcing its February sales, the Company is pleased to provide an update on its progress with Namaste’s medical cannabis telemedicine application, NamasteMD. During the month of...

Read More